Abstract
High PTH levels have been reported in patients with chronic heart failure (CHF). Similarly, its levels increase with aging and are related to impaired survival in elderly adults. However, its relationship with neuroendocrine activation and endothelial dysfunction in CHF has not been previously studied. Seventy-three CHF males with New York Heart Association (NYHA) classes II and III and 20 control subjects aged >55 yr were recruited. PTH, 25-hydroxyvita-min D [25(OH)D], N-terminal pro-brain natriuretic peptide (NT-pro-BNP), adiponectin, and osteoprotegerin were measured. Endothelial function (brachial flow mediated dilation), echocardiography, physical performance, and quality of life were assessed, as well. CHF patients had markedly increased serum PTH (77±33 vs 40±11 pg/ml, p<0.0001), NT-pro-BNP [1809 (2742) vs 67 (74) pg/ml, p<0.0001], adiponectin (17±9 vs 10±2 µg/ml, p<0.0001), osteoprotegerin, whereas 25(OH)D levels were decreased compared to controls. Increased PTH is positively correlated with NT-pro-BNP (r=0.399, p<0.0001), adiponectin (r=0.398, p<0.0001), and osteoprotegerin, whereas negatively with 25(OH)D in CHF patients. Additionally, increased serum PTH was associated with endothelial dysfunction, echocardiographic variables of heart failure progression, impaired physical performance, and deteriorated quality of life. In a multivariate linear regression analysis, increased serum PTH was independently associated with neuroendocrine activation (NT-pro-BNP, adiponectin) and endothelial dysfunction in elderly CHF men (R2=0.455). Additionally, demonstrated relations with other well-established variables of heart failure severity suggest the potential role of serum PTH in the pathogenesis and non-invasive monitoring of heart failure progression. Future studies are needed to evaluate the predictive value of serum PTH for clinical outcomes as well as beneficial potential of PTH suppression in CHF patients.
Similar content being viewed by others
References
Hobbs FD. The scale of heart failure: diagnosis and management issues for primary care. Heart 1999, 82: IV8–10.
Levy D, Kenchaiah S, Larson MG, Benjamin EJ, Kupka MJ, Ho KK, et al. Long-term trends in the incidence of and survival with heart failure. N Engl J Med 2002, 347: 1397–402.
Braunwald E. Biomarkers in heart failure. N Engl J Med 2008, 358: 2148–59.
Gunnarsson O, Indridason OS, Franzson L, Sigurdsson G. Factors associated with elevated or blunted PTH response in vitamin D insufficient adults. J Intern Med 2009, 265: 488–95.
Premaor MO, Scalco R, da Silva MJ, Furlanetto TW. Secondary hyperparathyroidism is associated with increased risk of hospitalization or death in elderly adults living in a geriatric institution. Gerontology 2009, 55: 405–10.
Shane E, Mancini D, Aaronson K, et al. Bone mass, vitamin D deficiency, and hyperparathyroidism in congestive heart failure. Am J Med 1997, 103: 197–207.
Sugimoto T, Tanigawa T, Onishi K, et al. Serum intact parathyroid hormone levels predict hospitalization for heart failure. Heart 2009, 95: 395–8.
Bhattacharya SK, Ahokas RA, Carbone LD, et al. Macro- and micronutrients in African-Americans with heart failure. Heart Fail Rev 2006, 11: 45–55.
Alsafwah S, Laguardia SP, Arroyo M, et al. Congestive heart failure is a systemic illness: a role for minerals and micronutrients. Clin Med Res 2007, 5: 238–43.
Chhokar VS, Sun Y, Bhattacharya SK, et al. Hyperparathyroidism and the calcium paradox of aldosteronism. Circulation 2005, 111: 871–8.
Saleh FN, Schirmer H, Sundsfjord J, Jorde R. Parathyroid hormone and left ventricular hypertrophy. Eur Heart J 2003, 24: 2054–60.
Tastan I, Schreckenberg R, Mufti S, Abdallah Y, Piper HM, Schlüter KD. Parathyroid hormone improves contractile performance of adult rat ventricular cardiomyocytes at low concentrations in a nonacute way. Cardiovasc Res 2009, 82: 77–83.
Okamoto H. Can adiponectin be a novel metabolic biomarker for heart failure? Circ J 2009, 73: 1012–3.
von Haehling S, Jankowska EA, Morgenthaler NG, et al. Comparison of midregional pro-atrial natriuretic peptide with N-terminal pro-B-type natriuretic peptide in predicting survival in patients with chronic heart failure. J Am Coll Cardiol 2007, 50: 1973–80.
Katz SD, Hryniewicz K, Hriljac I, et al. Vascular endothelial dysfunction and mortality risk in patients with chronic heart failure. Circulation 2005, 111: 310–4.
Fischer D, Rossa S, Landmesser U, et al. Endothelial dysfunction in patients with chronic heart failure is independently associated with increased incidence of hospitalization, cardiac transplantation, or death. Eur Heart J 2005, 26: 65–9.
Corretti MC, Anderson TJ, Benjamin EJ, et al. International Brachial Artery Reactivity Task Force. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol 2002, 39: 257–65.
Anker SD, Chua TP, Ponikowski P, et al. Hormonal changes and catabolic/anabolic imbalance in chronic heart failure and their importance for cardiac cachexia. Circulation 1997, 96: 526–34.
ATS statement: guidelines for the six-minute walk test. ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. Am J Respir Crit Care Med 2002, 166: 111–7.
Silvestry FE, Kerber RE, Brook MM, et al. Echocardiography-guided interventions. J Am Soc Echocardiogr 2009, 22: 213–31.
Devereux RB, Roman MJ, de Simone G, et al. Relations of left ventricular mass to demographic and hemodynamic variables in American Indians: the Strong Heart Study. Circulation 1997, 96: 1416–23.
Rector TS, Cohn JN. Assessment of patient outcome with the Minnesota Living with Heart Failure questionnaire: Reliability and validity during a randomized, double-blind, placebo-controlled trial of pimobendan. Pimobendan Multicenter Research Group. Am Heart J 1992, 124: 1017–25.
Cockroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976, 16: 31–41.
Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 1982, 143: 29–36.
Zittermann A, Schleithoff SS, Tenderich G, Berthold HK, Körfer R, Stehle P. Low vitamin D status: a contributing factor in the pathogenesis of congestive heart failure? J Am Coll Cardiol 2003, 41: 105–12.
George J, Patal S, Wexler D, et al. Circulating adiponectin concentrations in patients with congestive heart failure. Heart 2006, 92: 1420–24.
Tamura T, Furukawa Y, Taniguchi R, et al. Serum adiponectin level as an independent predictor of mortality in patients with congestive heart failure. Circ J 2007, 71: 623–30.
Sahota O, Masud T, San P, Hosking DJ. Vitamin D insufficiency increases bone turnover markers and enhances bone loss at the hip in patients with established vertebral osteoporosis. Clin Endocrinol (Oxf) 1999, 51: 217–21.
Lee NK, Sowa H, Hinoi E, Ferron M, Ahn JD, Confavreux C, et al. Endocrine regulation of energy metabolism by the skeleton. Cell 2007, 130: 456–69.
Confavreux CB, Levine R, Karsent G. A paradigm of integrative physiology, the crosstalk between bone and energy metabolisms. Mol Cell Endocrinol 2009, 310: 21–9.
Omland T, Drazner MH, Uehland T, et al. Plasma osteoprotegerin levels in the general population: relation to indices of left ventricular structure and function. Hypertension 2007, 49: 1392–8.
Ueland T, Jemtland R, Godang K, et al. Prognostic value of osteoprotegerin in heart failure after acute myocardial infarction. J Am Coll Cardiol 2004, 44: 1970–6.
Wykretowicz A, Furmaniuk J, Smielecki J, et al. The oxygen stress index and levels of circulating interleukin-10 and interleukin-6 in patients with chronic heart failure. Int J Cardiol 2004, 94: 283–7.
McCarty MF. Secondary hyperparathyroidism promotes the acute phase response — a rationale for supplemental vitamin D in prevention of vascular events in the elderly. Med Hypotheses 2005, 64: 1022–6.
Qin L, Raggatt LJ, Partridge NC. Parathyroid hormone: a double-edged sword for bone metabolism. Trends Endocrinol Metab 2004, 15: 60–5.
Golledge J, Leicht AS, Crowther RG, et al. Determinants of endothelial function in a cohort of patients with peripheral artery disease. Cardiology 2008, 111: 51–6.
Shin JY, Shin YG, Chung CH. Elevated serum osteoprotegerin levels are associated with vascular endothelial dysfunction in type 2 diabetes. Diabetes Care 2006, 29: 1664–6.
Bittner V, Weiner DH, Yusuf S, et al. Prediction of mortality and morbidity with a 6-minute walk test in patients with left ventricular dysfunction. SOLVD Investigators. JAMA 1993, 270: 1702–7.
Nishimura R, Tajik AA. Quantitative hemodynamics by Doppler echocardiography: a noninvasive alternative to cardiac catheterization. Prog Cardiovasc Dis 1994, 36: 309–42.
Rihal C, Nishimura R, Hatle L, Bailey K, Tajik A. Systolic and diastolic dysfunction in patients with clinical diagnosis of dilated cardiomyopathy: relation to symptoms and prognosis. Circulation 1994, 90: 2772–9.
Rejnmark L, Vestergaard P, Brot C, Mosekilde L. Parathyroid response to vitamin D insufficiency: relations to bone, body composition and to lifestyle characteristics. Clin Endocrinol (Oxf) 2008, 69: 29–35.
Cohen N, Gorelik O, Almoznino-Sarafian D, et al. Renal dysfunction in congestive heart failure, pathophysiological and prognostic significance. Clin Nephrol. 2004, 61: 177–84.
Zittermann A, Schleithoff SS, Koerfer R. Markers of bone metabolism in congestive heart failure. Clin Chim Acta 2006, 366: 27–36.
Pilz S, März W, Wellnitz B, et al. Association of vitamin D deficiency with heart failure and sudden cardiac death in a large cross-sectional study of patients referred for coronary angiography. J Clin Endocrinol Metab 2008, 93: 3927–35.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Loncar, G., Bozic, B., Dimkovic, S. et al. Association of increased parathyroid hormone with neuroendocrine activation and endothelial dysfunction in elderly men with heart failure. J Endocrinol Invest 34, e78–e85 (2011). https://doi.org/10.1007/BF03347080
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03347080